Pasithea Therapeutics Corporation has released an investor presentation detailing its current corporate overview and ongoing projects. The presentation provides insights into the company's pipeline developments, including the clinical trial progress of its product candidate, PAS-004, for advanced cancer patients. It highlights the company's focus on advancing its clinical and preclinical candidates and discusses the design and conduct of its ongoing Phase 1 clinical trial. The presentation also addresses the company's plans for future operations, including the pursuit of new indications and the filing of regulatory documents. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on May 01, 2025, and is solely responsible for the information contained therein.